{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:47:34Z","timestamp":1787669254106,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR 14-10649"],"award-info":[{"award-number":["ESR 14-10649"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapeutic anti-PD-L1 antibodies are safe as a monotherapy, albeit with minimal efficacy in triple-negative breast cancer (TNBC). This trial aimed to test the safety and efficacy of Durvalumab and Paclitaxel in metastatic TNBC. In this open-label, one-arm trial, five cycles of weekly paclitaxel were delivered intravenously (IV) concurrent with Durvalumab that was given IV every 2\u00a0weeks. The combination was preceded by one cycle of paclitaxel alone, for immunological priming, followed by Durvalumab solo until disease progression or unacceptable toxicity. Between 2017 and 2019, 14 patients received at least one cycle of the combination therapy. The therapy was safe with no-dose limiting toxicity, except one case of skin lesions. Adverse events (AEs) were reported in 71% of patients, and there was no death due to the combination therapy. Regardless of grade, the most common AEs were headache and peripheral neuropathy, as each happened in four patients (29%), followed by fatigue and skin rash in three patients (21%) each. Grade 3\/4 AEs were experienced by three patients (21%), with the most common being headache and anemia, which happened in two patients (14%). The confirmed objective response rate (ORR) was observed in five patients with a median duration of 10.0\u00a0months. Median Progression-free survival (PFS) and overall survival (OS) were 5 and 20.7\u00a0months, respectively. The combination of Durvalumab and Paclitaxel is safe, leaving room for additional agents. This is the first report on the combination of Durvalumab and Paclitaxel in the treatment of TNBC (NCT02628132).<\/jats:p>","DOI":"10.1038\/s41598-021-98113-6","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T10:20:00Z","timestamp":1632738000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Hazem","family":"Ghebeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adher","family":"Al-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riham","family":"Eiada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilani","family":"Cabangon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahish","family":"Ajarim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausar","family":"Suleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Tulbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taher","family":"Al-Tweigeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"98113_CR1","doi-asserted-by":"crossref","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J Clin 69, 7-34, doi:10.3322\/caac.21551 (2019).","DOI":"10.3322\/caac.21551"},{"key":"98113_CR2","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1158\/0008-5472.CAN-11-13160008-5472","volume":"71","author":"WH Fridman","year":"2011","unstructured":"Fridman, W. H. et al. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 71, 5601\u20135605. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-13160008-5472 (2011).","journal-title":"Cancer Res."},{"key":"98113_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","volume":"11","author":"Z Liu","year":"2018","unstructured":"Liu, Z., Li, M., Jiang, Z. & Wang, X. A comprehensive immunologic portrait of triple-negative breast cancer. Transl. Oncol. 11, 311\u2013329. https:\/\/doi.org\/10.1016\/j.tranon.2018.01.011 (2018).","journal-title":"Transl. Oncol."},{"key":"98113_CR4","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1158\/1078-0432.CCR-07-0892","volume":"13","author":"TF Gajewski","year":"2007","unstructured":"Gajewski, T. F. Failure at the effector phase: Immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res. 13, 5256\u20135261. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0892 (2007).","journal-title":"Clin. Cancer Res."},{"key":"98113_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677\u2013704. https:\/\/doi.org\/10.1146\/annurev.immunol.26.021607.090331 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"98113_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou, W. & Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467\u2013477. https:\/\/doi.org\/10.1038\/nri2326 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"98113_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1593\/neo.05733","volume":"8","author":"H Ghebeh","year":"2006","unstructured":"Ghebeh, H. et al. The B7\u2013H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors. Neoplasia 8, 190\u2013198. https:\/\/doi.org\/10.1593\/neo.05733 (2006).","journal-title":"Neoplasia"},{"key":"98113_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf, E. A. et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2, 361\u2013370. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0127 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"98113_CR9","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda, R. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460\u20132467. https:\/\/doi.org\/10.1200\/JCO.2015.64.8931 (2016).","journal-title":"J. Clin. Oncol."},{"key":"98113_CR10","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121. https:\/\/doi.org\/10.1056\/NEJMoa1809615 (2018).","journal-title":"N. Engl. J. Med."},{"key":"98113_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams, S. et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Ann. Oncol. 30, 397\u2013404. https:\/\/doi.org\/10.1093\/annonc\/mdy517 (2019).","journal-title":"Ann. Oncol."},{"key":"98113_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","volume":"5","author":"LA Emens","year":"2019","unstructured":"Emens, L. A. et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 STUDY. JAMA Oncol. 5, 74\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4224 (2019).","journal-title":"JAMA Oncol."},{"key":"98113_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams, S. et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. Ann. Oncol. 30, 405\u2013411. https:\/\/doi.org\/10.1093\/annonc\/mdy518 (2019).","journal-title":"Ann. Oncol."},{"key":"98113_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/14712598.2019.1635115","volume":"19","author":"J Alvarez-Argote","year":"2019","unstructured":"Alvarez-Argote, J. & Dasanu, C. A. Durvalumab in cancer medicine: A comprehensive review. Expert Opin. Biol. Ther. 19, 927\u2013935. https:\/\/doi.org\/10.1080\/14712598.2019.1635115 (2019).","journal-title":"Expert Opin. Biol. Ther."},{"key":"98113_CR15","doi-asserted-by":"publisher","first-page":"e000504","DOI":"10.1136\/esmoopen-2019-000504","volume":"4","author":"R Caparica","year":"2019","unstructured":"Caparica, R., Lambertini, M. & de Azambuja, E. How I treat metastatic triple-negative breast cancer. ESMO Open 4, e000504. https:\/\/doi.org\/10.1136\/esmoopen-2019-000504 (2019).","journal-title":"ESMO Open"},{"key":"98113_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1179\/joc.2011.23.5.295","volume":"23","author":"W Gong","year":"2011","unstructured":"Gong, W. et al. Paclitaxel induced B7-H1 expression in cancer cells via the MAPK pathway. J. Chemother. 23, 295\u2013299. https:\/\/doi.org\/10.1179\/joc.2011.23.5.295 (2011).","journal-title":"J. Chemother."},{"key":"98113_CR17","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","volume":"75","author":"J Peng","year":"2015","unstructured":"Peng, J. et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 75, 5034\u20135045. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3098 (2015).","journal-title":"Cancer Res."},{"key":"98113_CR18","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1186\/bcr2605","volume":"12","author":"H Ghebeh","year":"2010","unstructured":"Ghebeh, H. et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: Role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res. 12, R48. https:\/\/doi.org\/10.1186\/bcr2605 (2010).","journal-title":"Breast Cancer Res."},{"key":"98113_CR19","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","volume":"111","author":"T Azuma","year":"2008","unstructured":"Azuma, T. et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635\u20133643. https:\/\/doi.org\/10.1182\/blood-2007-11-123141 (2008).","journal-title":"Blood"},{"key":"98113_CR20","first-page":"3025","volume":"7","author":"S Demaria","year":"2001","unstructured":"Demaria, S. et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin. Cancer Res. 7, 3025\u20133030 (2001).","journal-title":"Clin. Cancer Res."},{"key":"98113_CR21","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.amjcard.2005.09.081","volume":"97","author":"G Sardella","year":"2006","unstructured":"Sardella, G. et al. Comparison between sirolimus- and paclitaxel-eluting stent in T-cell subsets redistribution. Am. J. Cardiol. 97, 494\u2013498. https:\/\/doi.org\/10.1016\/j.amjcard.2005.09.081 (2006).","journal-title":"Am. J. Cardiol."},{"key":"98113_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567. https:\/\/doi.org\/10.1038\/nature14011 (2014).","journal-title":"Nature"},{"key":"98113_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. Cancer"},{"key":"98113_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259\u2013271. https:\/\/doi.org\/10.1093\/annonc\/mdu450 (2015).","journal-title":"Ann. Oncol."},{"key":"98113_CR25","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer 109, 1721\u20131728. https:\/\/doi.org\/10.1002\/cncr.22618 (2007).","journal-title":"Cancer"},{"key":"98113_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/1471-2407-7-222","volume":"7","author":"N Elkum","year":"2007","unstructured":"Elkum, N. et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience. BMC Cancer 7, 222. https:\/\/doi.org\/10.1186\/1471-2407-7-222 (2007).","journal-title":"BMC Cancer"},{"key":"98113_CR27","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.12659\/AJCR.918770","volume":"20","author":"AD Al Sayed","year":"2019","unstructured":"Al Sayed, A. D., Elshenawy, M. A., Tulbah, A., Al-Tweigeri, T. & Ghebeh, H. Complete response of chemo-refractory metastatic metaplastic breast cancer to paclitaxel-immunotherapy combination. Am. J. Case Rep. 20, 1630\u20131635. https:\/\/doi.org\/10.12659\/AJCR.918770 (2019).","journal-title":"Am. J. Case Rep."},{"key":"98113_CR28","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","volume":"28","author":"H Kennecke","year":"2010","unstructured":"Kennecke, H. et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28, 3271\u20133277. https:\/\/doi.org\/10.1200\/JCO.2009.25.9820 (2010).","journal-title":"J. Clin. Oncol."},{"key":"98113_CR29","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/annonc\/mdu025","volume":"25","author":"A Awada","year":"2014","unstructured":"Awada, A. et al. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann. Oncol. 25, 824\u2013831. https:\/\/doi.org\/10.1093\/annonc\/mdu025 (2014).","journal-title":"Ann. Oncol."},{"key":"98113_CR30","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","volume":"18","author":"SB Kim","year":"2017","unstructured":"Kim, S. B. et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 18, 1360\u20131372. https:\/\/doi.org\/10.1016\/S1470-2045(17)30450-3 (2017).","journal-title":"Lancet Oncol."},{"key":"98113_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.19.00368","volume":"38","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial. J. Clin. Oncol. 38, 423\u2013433. https:\/\/doi.org\/10.1200\/JCO.19.00368 (2020).","journal-title":"J. Clin. Oncol."},{"key":"98113_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.801","author":"D Miles","year":"2021","unstructured":"Miles, D. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.801 (2021).","journal-title":"Ann. Oncol."},{"key":"98113_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3747\/co.2007.96","volume":"14","author":"JA Maroun","year":"2007","unstructured":"Maroun, J. A. et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: A consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr. Oncol. 14, 13\u201320. https:\/\/doi.org\/10.3747\/co.2007.96 (2007).","journal-title":"Curr. Oncol."},{"key":"98113_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jegh.2017.10.001","volume":"7","author":"A Alotaibi","year":"2017","unstructured":"Alotaibi, A., Perry, L., Gholizadeh, L. & Al-Ganmi, A. Incidence and prevalence rates of diabetes mellitus in Saudi Arabia: An overview. J. Epidemiol. Glob. Health 7, 211\u2013218. https:\/\/doi.org\/10.1016\/j.jegh.2017.10.001 (2017).","journal-title":"J. Epidemiol. Glob. Health"},{"key":"98113_CR35","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9 (2020).","journal-title":"Lancet"},{"key":"98113_CR36","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi, V. J. et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 152, 1128\u20131136. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2226 (2016).","journal-title":"JAMA Dermatol."},{"key":"98113_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4103\/0253-7613.56065","volume":"41","author":"B Vasudevan","year":"2009","unstructured":"Vasudevan, B., Sawhney, M. P. & Sharma, N. Docetaxel-induced photolichenoid eruption. Indian J. Pharmacol. 41, 203\u2013204. https:\/\/doi.org\/10.4103\/0253-7613.56065 (2009).","journal-title":"Indian J. Pharmacol."},{"key":"98113_CR38","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3389\/fonc.2018.00405","volume":"8","author":"M Donaldson","year":"2018","unstructured":"Donaldson, M., Owen, J. L., Chae, Y. K. & Choi, J. N. Management of persistent pruritus and lichenoid reaction secondary to nivolumab with narrowband ultraviolet B phototherapy. Front. Oncol. 8, 405. https:\/\/doi.org\/10.3389\/fonc.2018.00405 (2018).","journal-title":"Front. Oncol."},{"key":"98113_CR39","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.jtho.2017.08.007","volume":"12","author":"S Feng","year":"2017","unstructured":"Feng, S. et al. Pembrolizumab-induced encephalopathy: A review of neurological toxicities with immune checkpoint inhibitors. J. Thorac. Oncol. 12, 1626\u20131635. https:\/\/doi.org\/10.1016\/j.jtho.2017.08.007 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"98113_CR40","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1200\/JCO.2011.38.7886","volume":"30","author":"M Maur","year":"2012","unstructured":"Maur, M. et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J. Clin. Oncol. 30, e76-78. https:\/\/doi.org\/10.1200\/JCO.2011.38.7886 (2012).","journal-title":"J. Clin. Oncol."},{"key":"98113_CR41","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1093\/annonc\/mdt276","volume":"24","author":"DW Miles","year":"2013","unstructured":"Miles, D. W. et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients. Ann. Oncol. 24, 2773\u20132780. https:\/\/doi.org\/10.1093\/annonc\/mdt276 (2013).","journal-title":"Ann. Oncol."},{"key":"98113_CR42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2018.5152","volume":"5","author":"S Adams","year":"2019","unstructured":"Adams, S. et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: A phase 1b clinical trial. JAMA Oncol. 5, 334\u2013342. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5152 (2019).","journal-title":"JAMA Oncol."},{"key":"98113_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3816\/CBC.2009.n.005","volume":"9","author":"F Kassam","year":"2009","unstructured":"Kassam, F. et al. Survival outcomes for patients with metastatic triple-negative breast cancer: Implications for clinical practice and trial design. Clin. Breast Cancer 9, 29\u201333. https:\/\/doi.org\/10.3816\/CBC.2009.n.005 (2009).","journal-title":"Clin. Breast Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98113-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98113-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98113-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:15:25Z","timestamp":1670084125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98113-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98113"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98113-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Taher Al-Tweigeri has received speaking honoraria from Roche, Novartis, and Lilly. He also received travel support from Roche and Novartis and has served on advisory committees for Roche, Lilly, and Novartis. Dr. Hazem Ghebeh received travel support from AstraZeneca. Other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19154"}}